Edwards Lifesciences (EW) – Research Analysts’ Weekly Ratings Changes

Posted by Linda Flegge on Nov 12th, 2024

Several brokerages have updated their recommendations and price targets on shares of Edwards Lifesciences (NYSE: EW) in the last few weeks:

10/30/2024 – Edwards Lifesciences was downgraded by analysts at Daiwa America from a “strong-buy” rating to a “hold” rating.
10/28/2024 – Edwards Lifesciences was upgraded by analysts at Sanford C. Bernstein from a “strong sell” rating to a “hold” rating.
10/25/2024 – Edwards Lifesciences had its price target raised by analysts at JPMorgan Chase & Co. from $72.00 to $78.00. They now have a “neutral” rating on the stock.
10/25/2024 – Edwards Lifesciences had its price target lowered by analysts at Piper Sandler from $73.00 to $70.00. They now have a “neutral” rating on the stock.
10/25/2024 – Edwards Lifesciences had its price target lowered by analysts at Robert W. Baird from $73.00 to $68.00. They now have a “neutral” rating on the stock.
10/25/2024 – Edwards Lifesciences had its price target lowered by analysts at Canaccord Genuity Group Inc. from $66.00 to $63.00. They now have a “hold” rating on the stock.
10/25/2024 – Edwards Lifesciences had its price target lowered by analysts at Truist Financial Co. from $71.00 to $70.00. They now have a “hold” rating on the stock.
10/11/2024 – Edwards Lifesciences had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $70.00 price target on the stock.
10/8/2024 – Edwards Lifesciences had its price target lowered by analysts at Royal Bank of Canada from $85.00 to $75.00. They now have an “outperform” rating on the stock.
10/7/2024 – Edwards Lifesciences had its price target lowered by analysts at Canaccord Genuity Group Inc. from $77.00 to $66.00. They now have a “hold” rating on the stock.
10/1/2024 – Edwards Lifesciences had its price target lowered by analysts at Evercore ISI from $76.00 to $70.00. They now have an “in-line” rating on the stock.
10/1/2024 – Edwards Lifesciences had its price target lowered by analysts at Citigroup Inc. from $83.00 to $77.00. They now have a “buy” rating on the stock.
9/18/2024 – Edwards Lifesciences was downgraded by analysts at Jefferies Financial Group Inc. from a “buy” rating to a “hold” rating. They now have a $70.00 price target on the stock, down previously from $85.00.
9/13/2024 – Edwards Lifesciences had its price target lowered by analysts at Truist Financial Co. from $82.00 to $71.00. They now have a “hold” rating on the stock.

Edwards Lifesciences Stock Performance

Shares of NYSE EW traded down $1.51 during midday trading on Tuesday, hitting $65.19. The company’s stock had a trading volume of 1,876,107 shares, compared to its average volume of 4,622,983. The company has a current ratio of 3.46, a quick ratio of 2.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The firm has a market capitalization of $38.45 billion, a price-to-earnings ratio of 9.41, a P/E/G ratio of 3.72 and a beta of 1.12. The stock has a fifty day moving average price of $67.53 and a 200 day moving average price of $76.65.

Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same period last year, the firm earned $0.59 EPS. On average, research analysts forecast that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,101,530.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 41,250 shares of company stock valued at $2,746,988 over the last quarter. 1.29% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors have recently bought and sold shares of the business. Crewe Advisors LLC purchased a new position in shares of Edwards Lifesciences in the first quarter valued at $28,000. First Community Trust NA purchased a new position in shares of Edwards Lifesciences in the 2nd quarter valued at $29,000. Webster Bank N. A. purchased a new position in Edwards Lifesciences in the second quarter valued at about $39,000. Versant Capital Management Inc lifted its position in shares of Edwards Lifesciences by 206.3% during the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after buying an additional 326 shares during the last quarter. Finally, Prospera Private Wealth LLC acquired a new stake in Edwards Lifesciences in the third quarter valued at approximately $32,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.